Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) - Net Assets
Based on the latest financial reports, Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) has net assets worth CN¥15.04 Billion CNY (≈ $2.20 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥17.48 Billion ≈ $2.56 Billion USD) and total liabilities (CN¥2.44 Billion ≈ $356.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Zhangzhou Pientzehuang Pharmaceutical Co to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥15.04 Billion |
| % of Total Assets | 86.05% |
| Annual Growth Rate | 21.4% |
| 5-Year Change | 79.72% |
| 10-Year Change | 349.21% |
| Growth Volatility | 50.07 |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd - Net Assets Trend (2000–2024)
This chart illustrates how Zhangzhou Pientzehuang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Zhangzhou Pientzehuang Pharmaceutical Co for the complete picture of this company's asset base.
Annual Net Assets for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (2000–2024)
The table below shows the annual net assets of Zhangzhou Pientzehuang Pharmaceutical Co Ltd from 2000 to 2024. For live valuation and market cap data, see market value of Zhangzhou Pientzehuang Pharmaceutical Co.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥14.84 Billion ≈ $2.17 Billion |
+6.60% |
| 2023-12-31 | CN¥13.92 Billion ≈ $2.04 Billion |
+17.73% |
| 2022-12-31 | CN¥11.82 Billion ≈ $1.73 Billion |
+16.64% |
| 2021-12-31 | CN¥10.14 Billion ≈ $1.48 Billion |
+22.77% |
| 2020-12-31 | CN¥8.26 Billion ≈ $1.21 Billion |
+18.46% |
| 2019-12-31 | CN¥6.97 Billion ≈ $1.02 Billion |
+31.32% |
| 2018-12-31 | CN¥5.31 Billion ≈ $776.67 Million |
+19.94% |
| 2017-12-31 | CN¥4.43 Billion ≈ $647.55 Million |
+17.98% |
| 2016-12-31 | CN¥3.75 Billion ≈ $548.85 Million |
+13.54% |
| 2015-12-31 | CN¥3.30 Billion ≈ $483.38 Million |
+10.58% |
| 2014-12-31 | CN¥2.99 Billion ≈ $437.14 Million |
+15.24% |
| 2013-12-31 | CN¥2.59 Billion ≈ $379.33 Million |
+66.64% |
| 2012-12-31 | CN¥1.56 Billion ≈ $227.63 Million |
+30.83% |
| 2011-12-31 | CN¥1.19 Billion ≈ $173.99 Million |
+9.70% |
| 2010-12-31 | CN¥1.08 Billion ≈ $158.60 Million |
+26.44% |
| 2009-12-31 | CN¥857.19 Million ≈ $125.43 Million |
+13.97% |
| 2008-12-31 | CN¥752.09 Million ≈ $110.05 Million |
-0.89% |
| 2007-12-31 | CN¥758.85 Million ≈ $111.04 Million |
+22.18% |
| 2006-12-31 | CN¥621.09 Million ≈ $90.89 Million |
+2.14% |
| 2005-12-31 | CN¥608.07 Million ≈ $88.98 Million |
+12.80% |
| 2004-12-31 | CN¥539.08 Million ≈ $78.88 Million |
-2.62% |
| 2003-12-31 | CN¥553.59 Million ≈ $81.01 Million |
+257.60% |
| 2002-12-31 | CN¥154.81 Million ≈ $22.65 Million |
+6.02% |
| 2001-12-31 | CN¥146.02 Million ≈ $21.37 Million |
+3.30% |
| 2000-12-31 | CN¥141.35 Million ≈ $20.68 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhangzhou Pientzehuang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 89473.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥10.61 Billion | 74.32% |
| Common Stock | CN¥603.32 Million | 4.23% |
| Other Comprehensive Income | CN¥2.02 Billion | 14.13% |
| Other Components | CN¥1.05 Billion | 7.33% |
| Total Equity | CN¥14.27 Billion | 100.00% |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhangzhou Pientzehuang Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bankinter
MC:BKT
|
$12.50 Billion |
|
Air China Ltd Class A
SHG:601111
|
$12.50 Billion |
|
Nio Inc Class A ADR
NYSE:NIO
|
$12.52 Billion |
|
Embraer S.A.
SA:EMBR3
|
$12.52 Billion |
|
Evercore Partners Inc
NYSE:EVR
|
$12.47 Billion |
|
Align Technology Inc
NASDAQ:ALGN
|
$12.46 Billion |
|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
$12.45 Billion |
|
Gfl Environmental Holdings Inc
TO:GFL
|
$12.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhangzhou Pientzehuang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,376,325,404 to 14,271,727,825, a change of 895,402,421 (6.7%).
- Net income of 2,977,002,489 contributed positively to equity growth.
- Dividend payments of 2,127,271,717 reduced retained earnings.
- Other comprehensive income increased equity by 1,939,291,244.
- Other factors decreased equity by 1,893,619,595.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥2.98 Billion | +20.86% |
| Dividends Paid | CN¥2.13 Billion | -14.91% |
| Other Comprehensive Income | CN¥1.94 Billion | +13.59% |
| Other Changes | CN¥-1.89 Billion | -13.27% |
| Total Change | CN¥- | 6.69% |
Book Value vs Market Value Analysis
This analysis compares Zhangzhou Pientzehuang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 579.79x to 5.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | CN¥0.24 | CN¥141.30 | x |
| 2001-12-31 | CN¥0.25 | CN¥141.30 | x |
| 2002-12-31 | CN¥0.27 | CN¥141.30 | x |
| 2003-12-31 | CN¥0.94 | CN¥141.30 | x |
| 2004-12-31 | CN¥0.91 | CN¥141.30 | x |
| 2005-12-31 | CN¥1.00 | CN¥141.30 | x |
| 2006-12-31 | CN¥1.02 | CN¥141.30 | x |
| 2007-12-31 | CN¥1.25 | CN¥141.30 | x |
| 2008-12-31 | CN¥1.26 | CN¥141.30 | x |
| 2009-12-31 | CN¥1.43 | CN¥141.30 | x |
| 2010-12-31 | CN¥1.81 | CN¥141.30 | x |
| 2011-12-31 | CN¥1.98 | CN¥141.30 | x |
| 2012-12-31 | CN¥2.58 | CN¥141.30 | x |
| 2013-12-31 | CN¥4.25 | CN¥141.30 | x |
| 2014-12-31 | CN¥4.82 | CN¥141.30 | x |
| 2015-12-31 | CN¥5.21 | CN¥141.30 | x |
| 2016-12-31 | CN¥5.80 | CN¥141.30 | x |
| 2017-12-31 | CN¥6.87 | CN¥141.30 | x |
| 2018-12-31 | CN¥8.30 | CN¥141.30 | x |
| 2019-12-31 | CN¥10.99 | CN¥141.30 | x |
| 2020-12-31 | CN¥13.03 | CN¥141.30 | x |
| 2021-12-31 | CN¥16.09 | CN¥141.30 | x |
| 2022-12-31 | CN¥18.78 | CN¥141.30 | x |
| 2023-12-31 | CN¥22.19 | CN¥141.30 | x |
| 2024-12-31 | CN¥23.63 | CN¥141.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhangzhou Pientzehuang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.86%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 27.60%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.23x
- Recent ROE (20.86%) is above the historical average (20.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 35.41% | 27.21% | 0.71x | 1.83x | CN¥35.92 Million |
| 2001 | 35.72% | 26.90% | 0.72x | 1.85x | CN¥37.56 Million |
| 2002 | 37.98% | 27.73% | 0.65x | 2.10x | CN¥43.31 Million |
| 2003 | 11.14% | 28.31% | 0.36x | 1.10x | CN¥6.19 Million |
| 2004 | 7.91% | 16.48% | 0.45x | 1.06x | CN¥-11.06 Million |
| 2005 | 14.94% | 20.63% | 0.60x | 1.20x | CN¥28.56 Million |
| 2006 | 13.88% | 15.69% | 0.71x | 1.24x | CN¥22.90 Million |
| 2007 | 13.16% | 16.05% | 0.61x | 1.34x | CN¥22.88 Million |
| 2008 | 19.40% | 21.68% | 0.61x | 1.47x | CN¥68.25 Million |
| 2009 | 15.72% | 18.66% | 0.54x | 1.56x | CN¥47.20 Million |
| 2010 | 18.50% | 22.38% | 0.60x | 1.38x | CN¥89.18 Million |
| 2011 | 22.14% | 24.95% | 0.65x | 1.36x | CN¥139.74 Million |
| 2012 | 23.23% | 29.76% | 0.52x | 1.49x | CN¥198.51 Million |
| 2013 | 17.15% | 30.79% | 0.43x | 1.30x | CN¥179.14 Million |
| 2014 | 15.09% | 30.18% | 0.40x | 1.25x | CN¥147.98 Million |
| 2015 | 14.79% | 24.75% | 0.47x | 1.29x | CN¥151.14 Million |
| 2016 | 15.35% | 23.22% | 0.46x | 1.44x | CN¥186.79 Million |
| 2017 | 19.51% | 21.73% | 0.66x | 1.37x | CN¥393.41 Million |
| 2018 | 22.78% | 23.98% | 0.72x | 1.33x | CN¥641.28 Million |
| 2019 | 20.73% | 24.02% | 0.65x | 1.33x | CN¥711.24 Million |
| 2020 | 21.26% | 25.67% | 0.64x | 1.30x | CN¥885.30 Million |
| 2021 | 25.06% | 30.32% | 0.64x | 1.29x | CN¥1.46 Billion |
| 2022 | 21.82% | 28.44% | 0.60x | 1.29x | CN¥1.34 Billion |
| 2023 | 20.91% | 27.81% | 0.59x | 1.28x | CN¥1.46 Billion |
| 2024 | 20.86% | 27.60% | 0.62x | 1.23x | CN¥1.55 Billion |
Industry Comparison
This section compares Zhangzhou Pientzehuang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $2,267,139,914
- Average return on equity (ROE) among peers: 0.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) | CN¥15.04 Billion | 35.41% | 0.16x | $12.47 Billion |
| Zhejiang Int'L Group Co Ltd (000411) | $299.57 Million | 11.06% | 0.83x | $819.45 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $34.35 Million | 19.93% | 2.59x | $402.88 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $2.86 Billion | 6.53% | 0.83x | $907.61 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $531.76 Million | 1.61% | 0.66x | $378.52 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $469.52 Million | -49.05% | 1.48x | $2.00 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $48.97 Million | 5.65% | 0.47x | $412.17 Million |
| Sichuan Kelun Pharmaceutical Co Ltd (002422) | $13.91 Billion | 6.74% | 1.26x | $7.95 Billion |
| Chongqing Lummy Pharmaceutical (300006) | $1.23 Billion | -26.53% | 1.56x | $1.01 Billion |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $2.77 Billion | 13.80% | 0.31x | $1.56 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $513.55 Million | 19.39% | 0.03x | $1.94 Billion |
About Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Zhangzhou Pientzehuang Pharmaceutical., Ltd, together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally. It offers Chinese medicines in various forms, including capsules, tablets, pills, syrups, and ointments, as well as health care food and functional drinks, special efficacy cosmetics, and household chemicals under the Pien Tze Huang … Read more